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pleted Patient Record Forms (PRFs); pts self-reported data including EQ-5D and the 
Work Productivity and Activity Impairment Index for SLE (WPAI-Lupus) in Patient 
Self-Completion Records (PSCs). Pt eligibility was determined by physicians; disease 
activity and severity were based on physician assessment. Data across countries 
were pooled. Results: Data were collected from rheumatologists in the USA (n= 97), 
France (n= 37) and Germany (n= 35), including PRFs (550/200/207, respectively) and 
PSCs (303/109/149, respectively). Physician assessment of disease severity was pre-
dominantly based on affected organs and symptoms (45% and 35% of rheumatolo-
gists, respectively); 15% based severity on test results/clinical assessments. No disease 
activity index was widely used, 58% used their own assessment. Physician assessment 
of severity was imperfectly correlated with control of disease activity (activity con-
trolled in 56.1% of “moderate-to-severe” pts, uncontrolled in 6.1% of “mild” pts). Pts 
with “moderate-to-severe” severity presented with greater severity and organ involve-
ment, and a higher proportion experienced flares per 12-month period than “mild” 
pts (78.4% vs 52.6%). “Moderate-to-severe” severity was associated with a greater 
impact on HRQoL (EQ-5D: 0.72 vs 0.86; WPAI: 35.0 vs 16.3) than “mild” disease. Fewer 
“moderate-to-severe” pts were employed (full-time employment: 35.8% vs 48.8%), 
and a higher proportion required a care provider (6.6% vs 3.3%). ConClusions: SLE 
severity is not consistently assessed or defined in clinical practice: measures used in 
clinical trials are not routinely adopted in daily practice, whilst organ involvement 
and symptoms are central to physician assessment of severity. Correlation between 
severity and control of disease activity is imperfect. “Moderate-to-severe” severity is 
associated with a greater burden than “mild” disease.
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objeCtives: Heavy-light chain (HLC) quantitative test can identity and quan-
tify the heavy and light chain of each immunoglobulin class. The purpose of this 
study was to evaluate the effectiveness of HLC quantitative test. Methods: To 
evaluate the effectiveness of HLC quantitative test, systemic literature review using 
Ovid-MEDLINE, EMBASE, Cochrane library and eight domestic databases including 
KoreaMED had performed until October 10th, 2013. We included five cohort studies 
and one diagnostic evaluation study in the final evaluation. Two reviewers inde-
pendently assessed the quality of included studies and extracted data on study. 
The qualities of these studies were assessed according to Scottish Intercollegiate 
Guidelines Network (SIGN) tool. Results: The correlation between HLC quanti-
tative test with previous tests was evaluated in one study which patients with 
increased monoclonal IgA were enrolled, and the correlation coefficient with com-
parator tests was reported as 0.94 in that study. Clinical significance of quantitative 
HLC test for predicting prognosis was also reported in five cohort studies. Survival 
rate in patients with higher HLC ratio was significantly lower, and the increased 
IgA κ /λ ratio or IgM κ /λ ratio was significantly correlated with higher survival rate 
in patients with monoclonal gammaglobulinemia. The body of evidence as a whole 
suggests a Grade C for HLC quantitative test. ConClusions: HLC quantitative test 
is safe and effective test that can quantitatively measure the identified immuno-
globulin type and predict the prognosis of patients with monoclonal gammopathy.
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objeCtives: The CLL11 study (stage 2, NCT02053610; sponsored by F. Hoffmann-La 
Roche, Basel, Switzerland), compared G-Clb with R-Clb in 663 patients with previ-
ously untreated CLL and comorbidities. We compared the presence, disappearance 
and duration of absence of B-symptoms (fever, night sweats and weight loss) for 
G-Clb with R-Clb in CLL11. Methods: Patients were randomised to receive six 
28-day (D) cycles (C) of G-Clb (N= 333) or R-Clb (N= 330; G: 1000 mg D1, 8 and 15 C1, 
D1C2–6; R: 375 mg/m2 D1C1, 500 mg/m2 D1C2–6; Clb: 0.5 mg/kg D1 and 15 each 
cycle). B-symptoms were assessed by a physician at baseline, D1C1, D8C1, D1 of 
each subsequent cycle, 28 days after last study drug and every 3–6 months dur-
ing follow-up for progression-free survival. The data cut-off for this analysis was 
9thMay 2013. Results: At baseline, 260 patients had B-symptoms (n= 126, G-Clb; 
n= 134, R-Clb). During the treatment period, B-symptoms disappeared in 107 (85%) 
and 124 (93%) patients who received G-Clb and R-Clb, respectively (relative risk 
[RR]: 0.92, 95% confidence interval [CI]: 0.84–1.00; p= 0.0554). Median time to first 
disappearance of all B-symptoms was 32.0 days for G-Clb and 35.0 days for R-Clb 
(hazard ratio [HR]: 1.24,95% CI: 0.96–1.61; p= 0.103). At end of treatment, 96 (76%) 
and 108 (81%) patients who received G-Clb and R-Clb, respectively, were B-symptom 
free (RR: 0.95, 95% CI: 0.83–1.07; p= 0.3899). In patients whose B-symptoms disap-
peared, the 25% quartile for duration of absence of B-symptoms (median not 
reached) was 16.4 months for G-Clb and 10.4 months for R-Clb (HR: 0.59, 95% CI: 
0.36–0.97; p= 0.0387). ConClusions: There was no clinically meaningful difference 
in B-symptom freeness at end of treatment, however the absence of B-symptoms 
was prolonged by 6 months for G-Clb versus R-Clb.
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objeCtives: To compare the disease status and outcomes of patients with AS 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A multi-
D) CAT-Health scores of -1.2412 (1.6065) vs -0.0119 (1.3495) (p< 0.001). Patients tak-
ing opioids also showed worse scores: -1.1009 (1.9349) vs -0.3288 (1.4169) (p= 0.037). 
Differences on HRQoL according to antidepressant drugs were not statistically sig-
nificant. Episodes of pain during dialysis were concentrated in 24 patients who had 
6 or more painful sessions. These patients were taking analgesics more frequently 
(86.4% vs 36.9%; p< 0.001) and showed worse CAT-Health score: -1.5391 (1.6348) vs 
-0.3243 (1.4981) (p= 0.005). ConClusions: Pain during haemodialysis sessions is 
very common and requires the frequent use of analgesics, having a negative impact 
on patients’ HRQoL.
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objeCtives: COLLECT scale assesses comorbidities in patients with Chronic 
Lymphocytic Leukemia (CLL). Validation of COLLECT was a secondary objective 
of the MABERYC non-interventional study. The aim is to assess the clinical util-
ity and the validity of COLLECT to guide treatment regimen prescribed to CLL 
patients. Methods: MABERYC study included patients with CLL, being or not previ-
ously treated, initiating treatment with Rituximab+chemotherapy. COLLECT was 
administered at baseline and 12 months following treatment finalization. Treatment 
response (TR) and safety was also assessed in the last visit. COLLECT categorizes 
comorbidity in low (0-3), moderate (4-7) and high (> 7). Changes in COLLECT were 
categorized in improvement (reduction≥ 2), without changes (variation< 2) and 
worsening (increase≥ 2). Results: MABERYC included 218 patients, 179 completed 
COLLECT at baseline. Patients had a mean age of 67.5 years, 73% were male, 53% 
were naïve, 37% had moderate comorbidity and 27% high comorbidity. At baseline, 
42% of patients initiated treatment with Rituximab-Fludarabine-Ciclofosfamide 
(RFC), 30% with Rituximab-Bendamustine (RB), 18% with Rituximab-Clorambucile 
(RC) and 10% other patterns. Mean COLLECT score was higher in older patient, 
higher ECOG, previously treated (5.2 vs 4.2) and those receiving less aggressive treat-
ments (5.8 RC, 5.4 RB, 3.6 RFC). Changes in COLLECT were analysed in 134 patients. 
CR could be associated to improvement in comorbidity. Complete remission was 
reached by 53% of patients with COLLECT improvement, 47% without changes, and 
32% worsening. Number of adverse events (AEs) treatment related tend to be higher 
in patient with lower comorbidity (1.6 vs 0.9), using more aggressive treatments. 
Total number of AEs (related or not to treatment) tend to be higher in patients with 
higher comorbidity (7.8 vs 5.8). ConClusions: COLLECT scale assess comorbid-
ity which is related with patients’ profile, treatment regiment prescribed, CR and 
AEs. COLLECT could assist decision-making on the intensity of the chemotherapy 
regimen to prescribe.
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objeCtives: Psoriasis is a chronic inflammatory disease of the skin that cannot 
be cured. For patients with active moderate to severe psoriasis, biologics use is 
associated with an improvement in patients’ quality of life especially by reducing 
prevalence of psychological disorders. The objective of this study was to assess 
the impact of biologics use on depression and anxiety frequency and the number 
of medical visits. Methods: A retrospective study of the Quebec provincial drug 
reimbursement program (RAMQ) database was conducted using a randomly selected 
group of patients who have received at least one diagnosis of psoriasis between 
January 1st, 2007 and June 30th, 2012. To assess the impact of biologics use, time series 
analyses were performed. Time series analyses evaluate changes in the slope of a 
trend pre- and post-intervention, herein defined as biologics initiation. Trends in 
depression and anxiety frequency and medical visits frequency were compared for 
each year for a 5-year period before and after biologics initiation to assess the dif-
ferences in slopes. Results: A total of 43,400 patients with psoriasis were included 
in the study (mean age= 54.6 [SD= 21.9] years, 53.7% females), of which 1,108 (2.6%) 
used a biologic agent. For patients who needed to be treated with biologics, the 
rates of change in the depression and anxiety prevalence increased by 3.4% and by 
4.2% per year prior to biologics initiation respectively. After biologics initiation, the 
trends were still increasing, but at a statistically lower rate of 2.5% (p= 0.028) and of 
2.4% (p= 0.012) per year. Medical visits per patient increased during the 5-year period 
before biologics initiation. Visits frequency has reduced during the 5-year period 
after biologics initiation with a trend decreasing annually (p= 0.002). ConClusions: 
The present analysis illustrates that biologics use reduces the increase in depression 
and anxiety frequency and decreases the number of medical visits.
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objeCtives: To characterize the patient (pt) group classified by physicians as hav-
ing “moderate-to-severe” systemic lupus erythematosus (SLE) disease severity, and 
assess disease burden. Methods: Data were extracted from the Adelphi 2013 Lupus 
Disease-Specific Program, a multinational survey of clinical practice. Physicians com-
